Pulmonary Hypertension Journal Club: A Pilot Program Delivered via Twitter and Webinar

Final Outcomes Summary: Live Webinar and Twitter Chat Journal Club
August 2021 – March 2022
Grant ID: ME-2020-11003
This educational activity is supported by an educational grant from United Therapeutics Corporation.
Table of Contents

- Executive Summary (Slide 3)
- Activity Format (Slide 4)
- Educational Impact Summary (Slide 5)
- Program Insights (Slide 6)
- Audience Generation (Slide 7)
- Article Summaries (Slides 8-9)
- Executive Summary – Live Webinars (Slides 10-11)
- Level 1 – Live Webinars Participation (Slides 12-14)
- Level 2 & 3 – Live Webinars Satisfaction & Knowledge (Slide 15)
- Level 4 – Live Webinars Competence (Slides 16-18)
- Evaluation Data – Live Webinars (Slides 19-20)
- VuMedi Recordings - Live Webinars (Slides 21-23)
- Twitter Chat Outcomes (Slides 24-28)
- Accreditation (Slide 29)
Program Overview

This pilot Pulmonary Hypertension (PH) Journal Club program is delivered via Twitter, live webinar, and endured online. The multimedia PH Journal Club sessions are developed and moderated by NJH faculty on a monthly basis, with downloadable article summaries that provide the key points of recently published articles in PH and a group opinion developed by the National Jewish Health PH Program Providers. Each article summary issue is archived on a dedicated webpage. Every month, a thirty-minute live webinar led by expert NJH faculty provides a succinct article summary and engages participants in academic and peer discussion. The recording of each live webinar is endured on VuMedi and made available for a year. A 30-minute structured Twitter chat based on the same article is also offered each month, providing another forum for live interaction with peers and expert faculty, as well as ongoing Tweet exchange for those that cannot attend the live portion.

Program Chair & Faculty

- **Patricia George, MD**
  Associate Professor
  Division of Pulmonary, Critical Care & Sleep Medicine
  National Jewish Health

- **Mohammad Dalabih, MBBS, MHA**
  Assistant Professor
  Division of Pulmonary, Critical Care & Sleep Medicine
  National Jewish Health

Learning Objectives

- Utilize critical thinking and research analysis in the review of new data and guidelines in PH.
- Apply increased awareness and understanding of research, evidence and best practices to inform clinical practice in PH.
- Support an online community of practitioners to share key insights, latest research, and treatment strategies for patients with PH.

Program Webpage

**Launch Date:** August 18, 2021  
**End Date:** March 17, 2022  
[https://www.nationaljewish.org/phjournalc lub](https://www.nationaljewish.org/phjournalclub)

Target Audience & Accreditation

**Target Audience:** Pulmonologists, Cardiologists, Rheumatologists, Primary Care and Internal Medicine Physicians, Physician Assistants, and Nurse Practitioners who treat patients with PH.

**Accreditation:** National Jewish Health is accredited with Commendation by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

*NJH designates each of the 6 live activities (6 live webinars, 6 live Twitter chats) for a maximum of 0.5 AMA PRA Category 1 Credit™.*
## National Jewish Health Monthly PH Journal Club Activities

<table>
<thead>
<tr>
<th>Activity</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>Article Summary</td>
<td>6 article summaries developed</td>
</tr>
<tr>
<td>developed by NJH experts in PH</td>
<td></td>
</tr>
<tr>
<td>endured on NJH Website</td>
<td></td>
</tr>
<tr>
<td>Article Summary</td>
<td>306 article summary downloads</td>
</tr>
<tr>
<td>sent to target audience with registration</td>
<td></td>
</tr>
<tr>
<td>links to Zoom and Twitter Journal Club</td>
<td></td>
</tr>
<tr>
<td>Live Webinar Journal Club via Zoom</td>
<td>156 webinar participants</td>
</tr>
<tr>
<td>30-minute discussion led by NJH PH expert</td>
<td></td>
</tr>
<tr>
<td>(CME Credit)</td>
<td></td>
</tr>
<tr>
<td>Twitter Journal Club via Tweet Chat</td>
<td>47,880 impressions</td>
</tr>
<tr>
<td>(CME Credit)</td>
<td></td>
</tr>
<tr>
<td>Webinars Endured on Vu-Medi</td>
<td>1,159 views</td>
</tr>
</tbody>
</table>

- **6 article summaries developed**
- **306 article summary downloads**
- **156 webinar participants**
- **47,880 impressions**
- **1,159 views**
Webinar Participant Breakdown

- MD/DO: 43%
- PharmD: 14%
- RN: 8%
- NP: 7%
- PA: 2%
- Other: 26%

Total Participants = 156

Webinar participants reported confidence in integrating research findings into clinical practice

- Pre-activity (N=39): 63%
- Post-activity (N=22): 76%

21% relative gain in confidence
13% absolute gain in confidence

Webinar & Twitter Evaluation (N=20)

- 100% of respondents stated the learning objectives were met
- 81% of respondents increased their knowledge of PH
- 86% of respondents stated activity improved ability to treat or manage patients

Twitter Chat Highlights: August 2021 – March 2022

- Calendar Adds: 322
- Impressions: 47,880
- Hashtag Usage: 337
- Retweets: 61
- Likes: 447
- Replies: 105
- Engagements/Participants: 1585

Evaluation respondents intend to make changes to practice as a result of the activity

Potential Impact To 1,560 Patient Visits This Year

52% of participants were physicians and APPs
• In this pilot program, we found that most participants are not seeking credit for webinars or Twitter chats, though they are engaging with the content.
• Article downloads and endured video views are high, indicating high levels of participation in the educational content beyond the live activities.
• It appears not all Twitter chat participants are “active” in the live activity. However, based on data for engagements and likes, there are many viewers consuming the education presented without posting comments and actively contributing to the discussion.

“Our goal was to bring quality CME activities to colleagues and foster discussion over the latest studies and trials in pulmonary hypertension. The Twitter Journal Club was a fun way to push the envelope and offer free open access medical education to an even broader audience. We were grateful for the opportunity to share in learning with colleagues from around the country and world.”

– M. Patricia George, MD, PH Journal Club Program Co-Chair
**Personalized targeting tools** across numerous tactics reach HCPs by leveraging demographic data (such as location, profession, specialty) and behavioral data (such as learner participation history, areas of interest).

**Audience Generation**

Final Report

---

**Personalized + Customized Intelligent Marketing Platform**

- **Branded Channel on VuMedi**
- **CenterTable Twitter Follower & Advertising Campaign**
- **Personalized emails and e-newsletters**
- **Social media ads and posts**


*Data from 8/2021 – 3/2022*
November 2021 Article Summary: Comparative Efficacy and Safety of Targeted Therapies for Chronic Thromboembolic Pulmonary Hypertension: A Systematic Review and Network Meta-Analysis. Can Respir J. 2021 Sep 1;2021:1626971. View here.


Executive Summary – Live Webinars

Conclusions

- Patients with fibrosing ILD requiring supplemental oxygen have a significantly lower activity level
- Pulse INO can result in an improvement in physical activity, especially moderate and vigorous activity
- The treatment was well-tolerated
- A larger phase 3 study is underway (REBUILD)

Questions for Audience

- How does the data presented compare to your clinical practice, particularly in initial drug selection for intermediate risk patients?
- Will this study change how you care for patients with PAH?
- Is this data in conflict with TRITON (Initial oral triple vs dual combination in patients with PAH)? If the benefit of triple therapy observed in this study is to be attributed to addressing the three pathways (NO, ERA and prostacyclin pathway) why wasn’t this benefit observed in TRITON?
- What is the significance of overall survival being similar in the initial monotherapy and dual-combination therapy groups?
- Is this data generalizable to other common forms of PAH like SSc-PAH?
# Executive Summary – Live Webinars

Final Report

<table>
<thead>
<tr>
<th>Webinar Date</th>
<th>Article Title</th>
<th>Participants</th>
</tr>
</thead>
<tbody>
<tr>
<td>August 18, 2021</td>
<td>Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease, N Engl J Med. 2021;384(4):325-334.</td>
<td>39</td>
</tr>
<tr>
<td>November 17, 2021</td>
<td>Comparative Efficacy and Safety of Targeted Therapies for Chronic Thromboembolic Pulmonary Hypertension: A Systematic Review and Network Meta-Analysis. Can Respir J. 2021 Sep 1;2021:1626971.</td>
<td>20</td>
</tr>
</tbody>
</table>

**Total** 156
Level (1) Outcomes: PH Journal Club Webpage

Final Report

PH Journal Club Landing Page

https://www.nationaljewish.org/phjournalclub

3498 Page views
1416 Unique page views
306 Article summary downloads

Data as of 3/18/22
Level (1) Outcomes: Live Webinars Participation: By Degree

Final Report

- **MD/DO**: 68 participants (43%)
- **PharmD**: 22 participants (8%)
- **RN/LPN**: 12 participants (14%)
- **NP**: 11 participants (7%)
- **PA**: 3 participants (2%)
- **Other**: 40 participants (26%)

**Total Participants**: 156
Level (1) Outcomes: Live Webinars Participation: By Specialty

Final Report

<table>
<thead>
<tr>
<th>Specialty</th>
<th>Participants</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pulmonology</td>
<td>74</td>
</tr>
<tr>
<td>Cardiology</td>
<td>16</td>
</tr>
<tr>
<td>Pharmacy</td>
<td>14</td>
</tr>
<tr>
<td>Internal Medicine</td>
<td>13</td>
</tr>
<tr>
<td>Critical Care Medicine</td>
<td>9</td>
</tr>
<tr>
<td>Pediatrics</td>
<td>2</td>
</tr>
<tr>
<td>Surgery</td>
<td>2</td>
</tr>
<tr>
<td>Other</td>
<td>26</td>
</tr>
<tr>
<td><strong>Total Participants</strong></td>
<td><strong>156</strong></td>
</tr>
</tbody>
</table>
Evaluation respondents report they “Strongly Agree” or “Agree” that:

<table>
<thead>
<tr>
<th>Statement</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Material was presented in an objective manner and free of commercial bias</td>
<td>100%</td>
</tr>
<tr>
<td>Content presented was evidence-based and clinically relevant</td>
<td>100%</td>
</tr>
<tr>
<td>Activity improved my ability to treat or manage my patients</td>
<td>86%</td>
</tr>
<tr>
<td>Activity increased my knowledge of PH</td>
<td>81%</td>
</tr>
<tr>
<td>Learning objectives of this activity were met</td>
<td>100%</td>
</tr>
</tbody>
</table>

N=21
Level (4) Outcomes: Live Webinars Confidence

Evaluation respondents report they are “Very Confident” to “Somewhat Confident” in their ability to integrate the findings of the research article into clinical practice:

- **21% Relative Confidence Gain**
- **13% Absolute Confidence Gain**

Before Webinar (N=39): 63%
After Webinar (N=22): 76%
Level (4) Outcomes: Live Webinars Competence
Final Report

An analysis of open-ended comments demonstrates the following changes learners intend to make:

### Intended Changes by Activity

**August - Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease**

- Improve management of PH
- Treprostinil for ILD
- Lower threshold to treat
- Consult PH specialist
- Educate patients on treprostinil

**September - A Randomized, Double-Blind, Placebo-Controlled Study of Pulsed, Inhaled Nitric Oxide in Subjects at Risk of Pulmonary Hypertension Associated with Pulmonary Fibrosis**

- Recruit for Phase 3 trial
- Consider iNO for our PF patients

*78% of Evaluation respondents intend to make changes in practice as a result of the activity*
An analysis of open-ended comments demonstrates the following changes learners intend to make:

<table>
<thead>
<tr>
<th>Intended Changes by Activity</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>October - Association Between Initial Treatment Strategy and Long-term Survival in Pulmonary Arterial Hypertension</strong></td>
</tr>
<tr>
<td>• Consideration of agents</td>
</tr>
<tr>
<td><strong>February - Sotatercept for the Treatment of Pulmonary Arterial Hypertension</strong></td>
</tr>
<tr>
<td>• Incorporate new PH protocols</td>
</tr>
<tr>
<td>• Will use sotatercept as first choice when possible</td>
</tr>
<tr>
<td><strong>March - Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE study.</strong></td>
</tr>
<tr>
<td>• Treat PH group 3 with treprostinil</td>
</tr>
<tr>
<td>• Screen</td>
</tr>
</tbody>
</table>

Note: we did not receive evaluation data for November’s webinar titled “Comparative Efficacy and Safety of Targeted Therapies for Chronic Thromboembolic Pulmonary Hypertension: A Systematic Review and Network Meta-Analysis.”
Outcomes: Live Webinars
Final Report

Key Takeaways
• The efficacy of PH therapy
• 65% of ILD patients will develop PH.
• PH ILD inhaled treprostinil is beneficial
• Inhaled treprostinil was effective and tolerated
• New drug for PH
• Treatment options are emerging for these patients
• Treprostinil for PH-ILD

Future Topics
• Best practice for managing combined PH

August: Inhaled Treprostinil in Pulmonary Hypertension

September: Inhaled Nitric Oxide in Subjects at Risk of Pulmonary Hypertension

Key Takeaways
• The addition of triple agents early
• iNO may improve the PAH in PF patients
• How am I going to apply this study to my practice?
It helps providers to talk to patients about the clinical trial.

Questions
• Is echo sufficient to diagnose PH group?
• This study didn’t have a quality of life indicator, should it have?
• Would you pre consult to put a patient on a therapy for PAH without a right heart catheterization?
Outcomes: Live Webinars

October: Initial Treatment Strategy and Long-term Survival

Key Takeaways
• Promising treatments in PH-ILD

Discussion Questions
• How does the data presented compare to your clinical practice, particularly in initial drug selection for intermediate risk patients?
• Will this study change how you care with patients with PAH?
• Is this data in conflict with TRITON (Initial oral triple vs dual combination in patients with PAH)? If the benefit of triple therapy observed in this study is to be attributed to addressing the three pathways (NO, ERA and prostacyclin pathway) why wasn’t this benefit observed in TRITON?

February: Sotatercept for the Treatment of Pulmonary Arterial Hypertension

Key Takeaways
• Follow clinical study
• Sotatercept shows potential to treat PAH
• Using new drug in very important conditions like PAH

Future Topics
• Prevention articles on these concerns
• Idiopathic development of PH

March: Inhaled Treprostinil and Forced Vital Capacity

Key Takeaways
• Change noted in FVC
• Novel effects of treprostinil
• PH and ILD
• New knowledge

Future Topics
• Risk stratification
• More group 3
• PH and bronchiectasis

*Qualitative data not available for November
Outcomes: VuMedi Webinar Recordings

Final Report

National Jewish Health VuMedi Channel:
https://www.vumedi.com/channel/national-jewish-health/tab/journal-club/

August 18-19, 2021
• Recorded Zoom Webinar on VuMedi.

September 22-23, 2021
• Recorded Zoom Webinar on VuMedi.

October 20-21, 2021
• Recorded Zoom Webinar on VuMedi.
Outcomes: VuMedi Webinar Recordings
Final Report

National Jewish Health VuMedi Channel: https://www.vumedi.com/channel/national-jewish-health/tab/journal-club/

November 17, 2021
• November 2021 Article Summary: Comparative Efficacy and Safety of Targeted Therapies for Chronic Thromboembolic Pulmonary Hypertension: A Systematic Review and Network Meta-Analysis. Can Respir J. 2021 Sep 1;2021:1626971. View here.
  • Recorded Zoom Webinar on VuMedi.

February 16-17, 2022
  • Recorded Zoom Webinar on VuMedi.

March 16-17, 2022
  • Recorded Zoom Webinar on VuMedi.
Outcomes: VuMedi Webinar Recordings

Final Report

National Jewish Health VuMedi Channel:
https://www.vumedi.com/channel/national-jewish-health/tab/journal-club/

<table>
<thead>
<tr>
<th>Month</th>
<th>Impressions</th>
<th>Video Page Views</th>
<th>Unique Page Viewers</th>
<th>Starts</th>
<th>Unique Starts</th>
</tr>
</thead>
<tbody>
<tr>
<td>August</td>
<td>1130</td>
<td>251</td>
<td>175</td>
<td>117</td>
<td>95</td>
</tr>
<tr>
<td>September</td>
<td>470</td>
<td>224</td>
<td>137</td>
<td>94</td>
<td>68</td>
</tr>
<tr>
<td>October</td>
<td>587</td>
<td>132</td>
<td>90</td>
<td>54</td>
<td>37</td>
</tr>
<tr>
<td>November</td>
<td>932</td>
<td>201</td>
<td>134</td>
<td>96</td>
<td>75</td>
</tr>
<tr>
<td>February</td>
<td>369</td>
<td>245</td>
<td>151</td>
<td>133</td>
<td>104</td>
</tr>
<tr>
<td>March</td>
<td>227</td>
<td>106</td>
<td>76</td>
<td>62</td>
<td>49</td>
</tr>
<tr>
<td>Total</td>
<td>3,715</td>
<td>1,159</td>
<td>763</td>
<td>556</td>
<td>428</td>
</tr>
</tbody>
</table>

About VuMedi

- Nearly 14,000 registered pulmonary specialists, 67,265 cardiology specialists and over 96,000 primary care physicians (over 600,000 total)
- Distribution of video content to reach a large physician audience
- Analytics dashboard that shows video views, impressions, geolocation of viewers

Note: Heat map encompasses all 4 NJH Journal Clubs from 8/1/21-3/17/22
Twitter Handle: @NJHealthMedEd

Hashtag: #PHTwitterJC
## Executive Summary – Twitter Chats

**Final Report**

<table>
<thead>
<tr>
<th>Twitter Date</th>
<th>Article Title</th>
<th>Calendar Adds</th>
<th>Likes</th>
<th>Retweets</th>
<th>Hashtag Usage</th>
<th>Impressions</th>
<th>Engagements</th>
</tr>
</thead>
<tbody>
<tr>
<td>8/19/21</td>
<td>Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease</td>
<td>97</td>
<td>188</td>
<td>24</td>
<td>63</td>
<td>15,805</td>
<td>577</td>
</tr>
<tr>
<td>9/23/21</td>
<td>A Randomized, Double-Blind, Placebo-Controlled Study of Pulsed, Inhaled Nitric Oxide in Subjects at Risk of Pulmonary Hypertension Associated with Pulmonary Fibrosis</td>
<td>13</td>
<td>96</td>
<td>22</td>
<td>63</td>
<td>11,429</td>
<td>446</td>
</tr>
<tr>
<td>10/21/21</td>
<td>Association Between Initial Treatment Strategy and Long-term Survival in Pulmonary Arterial Hypertension</td>
<td>44</td>
<td>73</td>
<td>9</td>
<td>62</td>
<td>7,014</td>
<td>237</td>
</tr>
<tr>
<td>11/17/21</td>
<td>Comparative Efficacy and Safety of Targeted Therapies for Chronic Thromboembolic Pulmonary Hypertension: A Systematic Review and Network Meta-Analysis</td>
<td>11</td>
<td>30</td>
<td>1</td>
<td>56</td>
<td>7,114</td>
<td>126</td>
</tr>
</tbody>
</table>
## Executive Summary – Twitter Chats

### Final Report

<table>
<thead>
<tr>
<th>Twitter Date</th>
<th>Article Title</th>
<th>Calendar Adds</th>
<th>Likes</th>
<th>Retweets</th>
<th>Hashtag Usage</th>
<th>Impressions</th>
<th>Engagements</th>
</tr>
</thead>
<tbody>
<tr>
<td>2/17/22</td>
<td>Sotatercept for the Treatment of Pulmonary Arterial Hypertension</td>
<td>135</td>
<td>24</td>
<td>5</td>
<td>47</td>
<td>4,648</td>
<td>118</td>
</tr>
<tr>
<td>3/17/22</td>
<td>Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE study</td>
<td>22</td>
<td>36</td>
<td>0</td>
<td>46</td>
<td>1,870</td>
<td>81</td>
</tr>
<tr>
<td></td>
<td><strong>TOTALS</strong></td>
<td><strong>322</strong></td>
<td><strong>447</strong></td>
<td><strong>61</strong></td>
<td><strong>337</strong></td>
<td><strong>47,880</strong></td>
<td><strong>1,585</strong></td>
</tr>
</tbody>
</table>

**Definitions:**

**Impressions** - the number of impressions on a tweet sent in the selected date range. An impression is the number of times a tweet appears to users in either their timeline or search results.

**Engagements** - the total number of times a user interacted with the tweets sent during the selected date range.

*Engagements represent Twitter chat participants.*
August: Inhaled Treprostinil in PH Due to ILD

Patricia George, MD @PGEorgeMD · Aug 19
So in the last 3 minutes, I'll throw out an open question: What did you find most interesting about the INCREASE trial and do you have any other thoughts or takeaways? #PHILD #PHTwitterJC

National Jewish Health Medical Education @NJHealthMeJC · Aug 19
Here is question 2 #PHTwitterJC

Q2: Will the findings reported in this article change your practice? If so, please write how into the comments.
A. Yes - this article will change how I evaluate and treat patients with possible PH-ILD.
B. No.

15,805 Impressions

September: Inhaled Nitric Oxide

Irina Petrache @IrinaPetracheMD · Sep 23
Great JC by @georgeemd & @NJHealthMedEd discussing inhaled therapies in #pulmonaryhypertension #phild #phTwitterJC @Timlahn

Patricia George, MD @PGEorgeMD · Sep 23
My takeaways: Overall, both this study and the current clinical trial as well as the INCREASE study we discussed last month are quite exciting. After decades without effective therapies for #PHILD, we are finally making progress. #pulmonaryhypertension #PHTwitterJC

237 Engagements

October: Initial Treatment & Long-Term Survival

Patricia George, MD @PGEorgeMD · Oct 21
RESULTS: 1,611 pts were included in the final analysis: - The majority (81%) were on monotherapy. Most common monotherapy was oral ERA or PDE5-i - Most common dual-therapy ERA + PDE5-i - All triple combination patients were on a parenteral prostacyclin

Patricia George, MD @PGEorgeMD · Oct 21
Date of RHC was used as Initial date to assess survival in an intention-to-treat approach.
- Overall and transplant-free survival were represented using Kaplan-Meier method.
- 3 additional survival analyses were done using propensity score matching for age, sex, and PVR #PHTwitterJC

96 Likes on Tweets
PH Journal Club Twitter Highlights

Final Report

November: Chronic Thromboembolic Pulmonary Hypertension

- Patricia George, MD @PGGeorgeMD - Nov 17
- This is the only form of pulmonary hypertension potentially curable - by surgical intervention (CTEPH) (PHTwitterJC)
- Photo from McNeil and Dunning, Heart 2007

February: Sotatercept for Treatment of PAH

- Patricia George, MD @PGGeorgeMD - Feb 17
- Trial Design:
  - Primary endpoint = change in PVR at wk 24
  - Main 2nd endpoint = change in 6MWD at wk 24
- Other endpoints - changes in NT-proBNP, TAPSE, WHO FC, CAMP/HOR and SF-36 health survey scores (PHTwitterJC)

- Sotatercept 0.7 mg/kg
- Sotatercept 0.3 mg/kg
- Placebo

March: Inhaled Treprostinil and Forced Vital Capacity

- National Jewish Health Medical Education @NJHEducation - Mar 17
- Difference in change in FVC in 8 weeks (+84.5 mL, p = 0.1), 16 weeks (+168.5 mL, p = 0.011).
- 63% of patients with IPF were on antifibrotics (PHTwitterJC)

- National Jewish Health Medical Education @NJHEducation - Mar 17
- In subgroup analysis, patients with idiopathic pulmonary fibrosis showed a significant FVC difference at week 8 and at week 16.
- 19.3% (p=0.0043) of patients in the treatment group, vs. 3.9% in the placebo group (PHTwitterJC)

- National Jewish Health Medical Education @NJHEducation - Mar 17
- This corresponded to a statistically significant percent predicted difference in FVC of 1.8% (p=0.014) at 8 weeks and 1.8% (p=0.028) at 16 weeks (PHTwitterJC)

- National Jewish Health Medical Education @NJHEducation - Mar 17
- 84% patients were enrolled in the INCREASE study
- 146 (43%) had idiopathic interstitial pneumonia, of which 82 had IPF
- 82 (26%) had OPFE
- 72 (20%) had CTD-ILD
- 19 (6%) had chronic HP
- 2% had occupational lung disease (PHTwitterJC)
Accreditation

National Jewish Health is accredited with Commendation by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The NJH Office of Professional Education produced and accredited this program and adhered to the updated ACCME guidelines.

**Live Webinars**
National Jewish Health designates each live activity for a maximum of 0.5 *AMA PRA Category 1 Credit™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Live Twitter Chats**
National Jewish Health designates each Other activity (social media discussion) for a maximum of 0.5 *AMA PRA Category 1 Credit™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.